HUPO External Development Initiative (HEDI)

The Human Proteome Organization has established a HUPO External Development Initiative (HEDI) committee to foster integration between the HUPO membership and international thought leaders who are responsible for developing strategy for funding proteomic-centric projects in their respective countries.

The objectives of this initiative are:

Identifying emerging scientific opportunities, rising public health challenges, or scientific knowledge gaps that merit further research by international funding agencies, non-profit governmental organizations and foundations, hereafter called Funders.
Understanding scientific priorities and strategic planning of Funders globally in developing and applying resources (databases, analytic tools, and methodologies) and producing specifications for new resources in support of proteomic research
If requested, assisting the Funders to address areas of emerging scientific opportunities and public health challenges effectively
Proactively discussing and providing technical assistance to Funders in the development of proteomic-based initiatives.

Chair's Corner

NCI Early Detection Research Network Hosts 12th Scientific Workshop on Biomarkers for Early Detection of Cancer

We are pleased to announce the 13^th NCI Early Detection Research Network (EDRN) Scientific Workshop, which will be held virtually due to COVID-19 pandemic on March 23 through March 25, 2021. This year's event entitled, "20^th Year of EDRN: Making Cancer Detection Possible" will include both lectures and panel discussions. In the December 2020 issue, the AACR journal Cancer Biomarker, Epidemiology and Prevention published a CEBP Focus (https://cebp.aacrjournals.org/content/29/12#CEBPFocus) to highlight the remarkable progress in cancer early detection supported by EDRN.

EDRN is a consortium of investigators committed to translational research on cancer biomarkers and advancing them to clinical application. The main goals of the consortium are to enable population cancer screening, detection of cancers at an early stage, and ultimately reduction in morbidity and mortality. Major efforts are devoted to developing and validating cancer biomarkers and to creating the necessary infrastructure. The workshop will address various aspects of cancer biomarker development, including novel technologies that lead to the identification of biomarkers that hold promise for early detection of cancer and hurdles in translating basic science into clinical application. Experts in diverse fields will discuss how such wealth of information can be applied to develop biomarkers for risk assessment and early detection of cancer.

Several well-respected investigators have already consented to participate in the upcoming EDRN Scientific Workshop. I am sure this will be an informative and a worthwhile forum for discussion.

We already have more than 250 registered attendees and will close the registration soon https://www.compass.fhcrc.org/meeting/reg_edrn/edrnsc.aspx. I cordially invite you to attend and participate in the workshop. The agenda can be accessed through https://edrn.nci.nih.gov/groups/steering-committee/sci-12

Guest's Corner

Information coming soon.

Membership

Dr. Sudhir Srivastava (National Cancer Institute - National Institutes of Health USA) Senior Program Director Chair, HUPO External Development Initiative
Dr. Robert Moritz (HUPO Vice President and Institute for Systems Biology, Seattle WA USA) Co-Chair HUPO Development Initiative
Dr. Mike Snyder (HUPO Past President and Stanford University, CA USA) Co-Chair HUPO Development Initiative

Funding Opportunity in Single Cell Proteomics